Checkpoint Therapeutics (CKPT) Projected to Post Earnings on Friday

Checkpoint Therapeutics (NASDAQ:CKPT) is expected to be issuing its quarterly earnings data before the market opens on Friday, March 28th. Analysts expect the company to announce earnings of ($0.22) per share for the quarter.

Checkpoint Therapeutics Price Performance

Shares of NASDAQ CKPT opened at $4.06 on Friday. The company has a 50 day simple moving average of $3.22 and a 200 day simple moving average of $3.17. The firm has a market cap of $198.26 million, a PE ratio of -2.21 and a beta of 1.41. Checkpoint Therapeutics has a 1 year low of $1.38 and a 1 year high of $4.50.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on CKPT shares. Lake Street Capital restated a “hold” rating and set a $4.10 price target (down previously from $7.00) on shares of Checkpoint Therapeutics in a report on Monday, March 10th. HC Wainwright reaffirmed a “neutral” rating and set a $4.10 price objective on shares of Checkpoint Therapeutics in a research report on Tuesday, March 11th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $4.80 price objective (down previously from $9.00) on shares of Checkpoint Therapeutics in a research report on Monday, March 10th.

Insider Activity at Checkpoint Therapeutics

In other news, CEO James F. Oliviero III sold 9,233 shares of Checkpoint Therapeutics stock in a transaction on Friday, February 7th. The stock was sold at an average price of $3.41, for a total transaction of $31,484.53. Following the sale, the chief executive officer now directly owns 3,785,350 shares in the company, valued at $12,908,043.50. The trade was a 0.24 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO William Garrett Gray sold 74,110 shares of Checkpoint Therapeutics stock in a transaction on Thursday, February 6th. The stock was sold at an average price of $3.67, for a total value of $271,983.70. Following the sale, the chief financial officer now owns 1,458,644 shares in the company, valued at $5,353,223.48. The trade was a 4.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 93,674 shares of company stock valued at $336,011. 2.10% of the stock is owned by company insiders.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.